Voyager Therapeutics Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Voyager Therapeutics hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$0.056
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 05

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Mar 15

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Mar 08

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Mar 04

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Jan 04

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Oct 04

Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

May 12

Voyager Does A Reboot After First Generation Failures

Mar 25

Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky

Feb 07

Voyager Therapeutics: Another Year, Another Deal

Nov 21

Some Analysts Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

Aug 11

Newsflash: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Analysts Have Been Trimming Their Revenue Forecasts

Jul 18

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von VYGR in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von VYGR gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Voyager Therapeutics Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von VYGR im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (VYGR)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.7%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (VYGR)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von VYGR im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von VYGR im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von VYGR, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da VYGR keine Ausschüttungen gemeldet hat.

Voyager Therapeutics Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Consensus revenue estimates increase by 29%

Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting

Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Investor sentiment improves as stock rises 16%

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold US$119k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Consensus revenue estimates fall by 21%

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Investor sentiment improves as stock rises 18%

President recently sold US$97k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

New minor risk - Share price stability

Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Financial Officer recently sold US$95k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Chief Science Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 25%

Price target increased by 9.8% to US$11.17

Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

President recently sold US$58k worth of stock

Chief Operating Officer recently sold US$126k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$8.20

Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023

Consensus revenue estimates increase by 170%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Consensus forecasts updated

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO, Effective September 19, 2022

Voyager Therapeutics hires new finance chief

Consensus forecasts updated

Consensus revenue estimates fall by 86%

Second quarter 2022 earnings released: US$0.50 loss per share (vs US$0.80 loss in 2Q 2021)

Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

Voyager Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to Its Board of Directors

Voyager Therapeutics, Inc. Announces Executive Changes

Looking Back In On Voyager Therapeutics

Voyager Therapeutics, Inc. to Present New Preclinical Data on Family of AAV9-Derived Tracer Capsids Demonstrating Cross-Species Central Nervous System (CNS) Transduction

Voyager Therapeutics, Inc. to Present Preclinical Data from Its Vectorized Anti-Her2 Antibody Program and A Novel Aav5-Derived Tracer™ Capsid At the 25Th American Society of Gene and Cell Therapy Annual Meeting

Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

Consensus revenue estimates fall by 37%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$6.80

Voyager Therapeutics, Inc., Annual General Meeting, Jun 06, 2022

Mark Levin and Steven Paul Requests Voyager Therapeutics Not to Nominate for Re-Election to the Board

Voyager Does A Reboot After First Generation Failures